ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
89bio Initiates Trial of BIO89-100 for NASH
August 09, 201989Bio announced the first patients have been screened in its proof of concept Phase 1b/2a clinical trial evaluating its investigational product candidate, BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 (FGF21) ... -
89bio Reports Positive Top-line Data from Phase 1 Single-Ascending Dose Clinical Trial of BIO89-100
May 23, 201989bio LTD announced positive top-line results from a Phase 1 single ascending dose (SAD) study of its investigational medicine, BIO89-100, in healthy volunteers.
Pharma Sources Insight January 2025
